Search

Your search keyword '"Giugliano, Robert P"' showing total 2,073 results
Start Over Author "Giugliano, Robert P"
2,073 results on '"Giugliano, Robert P"'

4. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

Author

Patel, Siddharth M., Braunwald, Eugene, Steffel, Jan, Boriani, Giuseppe, Palazzolo, Michael G., Antman, Elliott M., Bohula, Erin A., Carnicelli, Anthony P., Connolly, Stuart J., Eikelboom, John W., Gencer, Baris, Granger, Christopher B., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Ruff, Christian T., and Giugliano, Robert P.

Published
2024
Full Text
View/download PDF

5. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Author

Peterson, Benjamin E, Bhatt, Deepak L, Steg, Ph Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Juliano, Rebecca A, Jiao, Lixia, DoyleJr., Ralph T, Granowitz, Craig, Gibson, C Michael, Pinto, Duane, Giugliano, Robert P, Budoff, Matthew J, Tardif, Jean‐Claude, Verma, Subodh, Ballantyne, Christie M, and Investigators, the REDUCE‐IT

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease, Clinical Research, Atherosclerosis, Heart Disease - Coronary Heart Disease, Prevention, Clinical Trials and Supportive Activities, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Double-Blind Method, Eicosapentaenoic Acid, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ischemia, Myocardial Infarction, Percutaneous Coronary Intervention, Risk Factors, Stroke, Treatment Outcome, Triglycerides, eicosapentaenoic acid, icosapent ethyl, prevention, revascularization, REDUCE‐IT Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Background Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical therapy. Methods and Results This post hoc analysis focused on the subset of patients with prior PCI enrolled in REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial), a multicenter, randomized, double-blind, placebo-controlled trial of icosapent ethyl versus placebo. Icosapent ethyl was added to statins in patients with low-density lipoprotein cholesterol

Published
2022

11. Abstract 12946: Among Patients With Acute Coronary Syndromes, is the Risk of Hyperglycemia for In-Hospital Mortality Similar in Men and Women?

Author

Nicolau, Jose C, Castro Vintimilla, Santiago A, Rosa, Renato, Bertolin, Adriadne J, Andrade, Maria C, Salis, Leonardo V, Montero Ribera, Jorge L, Quintanilha, Nadia R, Santos, Glaylton S, Baracioli, Luciano M, Giraldez, Roberto R, Lima, Felipe G, Pereira, Cesar C, Nicolau, Andre M, Furtado, Remo H, and Giugliano, Robert P

Published
2023
Full Text
View/download PDF

15. Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC

Author

Peterson, Benjamin E, Bhatt, Deepak L, Steg, Ph Gabriel, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Ketchum, Steven B, Juliano, Rebecca A, Jiao, Lixia, Doyle, Ralph T, Granowitz, Craig, Gibson, C Michael, Pinto, Duane, Giugliano, Robert P, Budoff, Matthew J, Tardif, Jean-Claude, Verma, Subodh, and Ballantyne, Christie M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Heart Disease, Atherosclerosis, Heart Disease - Coronary Heart Disease, Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Cardiovascular Diseases, Diabetes Mellitus, Double-Blind Method, Eicosapentaenoic Acid, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Myocardial Revascularization, Platelet Aggregation Inhibitors, eicosapentaenoic acid, icosapent ethyl, myocardial revascularization, prevention & control, REDUCE-IT Investigators, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences, Sports science and exercise
Abstract

BackgroundPatients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations.MethodsREDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigned statin-treated patients with elevated triglycerides (135-499 mg/dL), controlled low-density lipoprotein (41-100 mg/dL), and either established cardiovascular disease or diabetes plus other risk factors to receive icosapent ethyl 4 g/d or placebo. The primary and key secondary composite end points were significantly reduced. Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and revascularization subtypes.ResultsA total of 8179 randomly assigned patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio, 0.66 [95% CI, 0.58-0.76]; P

Published
2021

19. REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States

Author

Bhatt, Deepak L, Miller, Michael, Brinton, Eliot A, Jacobson, Terry A, Steg, Ph Gabriel, Ketchum, Steven B, Doyle, Ralph T, Juliano, Rebecca A, Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Olshansky, Brian, Chung, Mina K, Gibson, C Michael, Giugliano, Robert P, Budoff, Matthew J, and Ballantyne, Christie M

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Clinical Research, Cardiovascular, Clinical Trials and Supportive Activities, Heart Disease - Coronary Heart Disease, Atherosclerosis, Heart Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Cholesterol, LDL, Double-Blind Method, Eicosapentaenoic Acid, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Myocardial Infarction, Risk Factors, Stroke, United States, eicosapentaenoic acid ethyl ester, fatty acids, omega-3, lipids, prevention and control, triglycerides, REDUCE-IT Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences, Sports science and exercise
Abstract

BackgroundSome trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States.MethodsREDUCE-IT randomized 8179 statin-treated patients with qualifying triglycerides ≥135 and 40 and ≤100 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary composite end point was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. A hierarchy was prespecified for examination of individual and composite end points.ResultsA total of 3146 US patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women and 9.7% were Hispanic. The primary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59-0.80]; P=0.000001); the key secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 0.57-0.83]; P=0.00008). All prespecified hierarchical end points were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%; HR, 0.66 [95% CI, 0.49-0.90]; P=0.007), myocardial infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56-0.93]; P=0.01), stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43-0.93]; P=0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55-0.90]; P=0.004); for all-cause mortality in the US versus non-US patients, Pinteraction=0.02. Safety and tolerability findings were consistent with the full study cohort.ConclusionsWhereas the non-US subgroup showed significant reductions in the primary and key secondary end points, the US subgroup demonstrated particularly robust risk reductions across a variety of individual and composite end points, including all-cause mortality.Clinical trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01492361.

Published
2020

22. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

Author

Small, Aeron M., primary, Melloni, Giorgio E. M., additional, Kamanu, Frederick K., additional, Bergmark, Brian A., additional, Bonaca, Marc P., additional, O’Donoghue, Michelle L., additional, Giugliano, Robert P., additional, Scirica, Benjamin M., additional, Bhatt, Deepak, additional, Antman, Elliott M., additional, Raz, Itamar, additional, Wiviott, Stephen D., additional, Truong, Buu, additional, Wilson, Peter W. F., additional, Cho, Kelly, additional, O’Donnell, Christopher J., additional, Braunwald, Eugene, additional, Lubitz, Steve A., additional, Ellinor, Patrick, additional, Peloso, Gina M., additional, Ruff, Christian T., additional, Sabatine, Marc S., additional, Natarajan, Pradeep, additional, and Marston, Nicholas A., additional

Published
2024
Full Text
View/download PDF

23. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations

Author

Small, Aeron M., primary, Pournamdari, Ashley, additional, Melloni, Giorgio E.M., additional, Scirica, Benjamin M., additional, Bhatt, Deepak L., additional, Raz, Itamar, additional, Braunwald, Eugene, additional, Giugliano, Robert P., additional, Sabatine, Marc S., additional, Peloso, Gina M., additional, Marston, Nicholas A., additional, and Natarajan, Pradeep, additional

Published
2024
Full Text
View/download PDF

24. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease

Author

McClintick, Daniel J., primary, O’Donoghue, Michelle L., additional, De Ferrari, Gaetano M., additional, Ferreira, Jorge, additional, Ran, Xinhui, additional, Im, KyungAh, additional, López, J. Antonio G., additional, Elliott-Davey, Mary, additional, Wang, Bei, additional, Monsalvo, Maria Laura, additional, Atar, Dan, additional, Keech, Anthony, additional, Giugliano, Robert P., additional, and Sabatine, Marc S., additional

Published
2024
Full Text
View/download PDF

33. Platelet Reactivity and Coagulation Markers in Patients with COVID-19

Author

Bertolin, Adriadne J., Dalçóquio, Talia F., Salsoso, Rocío, de M. Furtado, Remo H., Kalil-Filho, Roberto, Hajjar, Ludhmila A., Siciliano, Rinaldo F., Kallás, Esper G., Baracioli, Luciano M., Lima, Felipe G., Giraldez, Roberto R., Cavalheiro-Filho, Cyrillo, Vieira, Alexandra, Strunz, Célia M. C., Giugliano, Robert P., Tantry, Udaya S., Gurbel, Paul A., and Nicolau, José C.

Published
2021
Full Text
View/download PDF

37. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Author

Sabatine, Marc S, Giugliano, Robert P, Keech, Anthony C, Honarpour, Narimon, Wiviott, Stephen D, Murphy, Sabina A, Kuder, Julia F, Wang, Huei, Liu, Thomas, Wasserman, Scott M, Sever, Peter S, Pedersen, Terje R, and FOURIER Steering Committee and Investigators

Subjects
FOURIER Steering Committee and Investigators, Humans, Cardiovascular Diseases, Hypercholesterolemia, Antibodies, Monoclonal, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Therapy, Combination, Incidence, Least-Squares Analysis, Follow-Up Studies, Double-Blind Method, Aged, Middle Aged, Female, Male, Atherosclerosis, Cholesterol, LDL, Antibodies, Monoclonal, Humanized, Proprotein Convertase 9, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, Heart Disease, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundEvolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.MethodsWe conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.ResultsAt 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P

Published
2017

42. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events

Author

Helgason, Hannes, primary, Eiriksdottir, Thjodbjorg, additional, Ulfarsson, Magnus O., additional, Choudhary, Abhishek, additional, Lund, Sigrun H., additional, Ivarsdottir, Erna V., additional, Hjorleifsson Eldjarn, Grimur, additional, Einarsson, Gudmundur, additional, Ferkingstad, Egil, additional, Moore, Kristjan H. S., additional, Honarpour, Narimon, additional, Liu, Thomas, additional, Wang, Huei, additional, Hucko, Thomas, additional, Sabatine, Marc S., additional, Morrow, David A., additional, Giugliano, Robert P., additional, Ostrowski, Sisse Rye, additional, Pedersen, Ole Birger, additional, Bundgaard, Henning, additional, Erikstrup, Christian, additional, Arnar, David O., additional, Thorgeirsson, Gudmundur, additional, Masson, Gísli, additional, Magnusson, Olafur Th., additional, Saemundsdottir, Jona, additional, Gretarsdottir, Solveig, additional, Steinthorsdottir, Valgerdur, additional, Thorleifsson, Gudmar, additional, Helgadottir, Anna, additional, Sulem, Patrick, additional, Thorsteinsdottir, Unnur, additional, Holm, Hilma, additional, Gudbjartsson, Daniel, additional, and Stefansson, Kari, additional

Published
2023
Full Text
View/download PDF

47. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P., Hong, Hwanhee, Connolly, Stuart J., Eikelboom, John, Giugliano, Robert P., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Alexander, John H., Cecilia Bahit, M., Benz, Alexander P., Bohula, Erin A., Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, A.A. Fox, Keith, Gencer, Baris, Halperin, Jonathan L., Hijazi, Ziad, Hohnloser, Stefan H., Hua, Kaiyuan, Hylek, Elaine, Toda Kato, Eri, Kuder, Julia, Lopes, Renato D., Mahaffey, Kenneth W., Oldgren, Jonas, Piccini, Jonathan P., Ruff, Christian T., Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B.

Published
2022
Full Text
View/download PDF

48. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Author

Verma, Subodh, Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Dhingra, Nitish K., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Jr., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Mason, R. Preston, Tardif, Jean-Claude, and Ballantyne, Christie M.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results